Biomx Inc (PHGE) - News Archive

BiomX Inc. a clinical-stage company specializing in phage therapy, continues to make strides in developing innovative treatments targeting pathogenic bacteria associated with chronic diseases. This article outlines the...

Outline of Facts:1. Positive Phase 2 Trial Results: - BiomX announced positive topline results from its Phase 2 trial evaluating BX211 for the treatment of Diabetic Foot Osteomyelitis (DFO). - A conference call and webc...

BiomX Inc. Reclaims NYSE Standing as Cystic Fibrosis Treatments Take Center StageNESS ZIONA, Israel - December 16, 2024 - BiomX Inc. (NYSE American: PHGE), a clinical-stage biotechnology company recognized for advancing...

A New Frontier in Cystic Fibrosis Treatment: BiomX s Promising Data on BX004:In a significant development for cystic fibrosis (CF) management, BiomX Inc. a company at the forefront of phage therapy exploration, is set t...

Cystic fibrosis (CF) remains a formidable challenge in respiratory medicine, characterized by chronic pulmonary infections most commonly associated with Pseudomonas aeruginosa . Recent developments from BiomX Inc. a pio...

In a recent press release, BiomX Inc. (NYSE American: PHGE) announced its decision to effect a one-for-ten reverse stock split (the Reverse Stock Split) of the Company s common stock. This move is aimed at adjusting out...

BiomX Inc. Implements Reverse Stock Split and Stockholder Approval for Preferred Stock ConversionBiomX Inc., a clinical-stage company specializing in phage therapies targeting pathogenic bacteria, recently announced a o...

GAITHERSBURG, Md. - BiomX Inc. (NYSE American: PHGE) made a significant announcement today regarding a proposal to convert its outstanding Series X Non-Voting Convertible Preferred Stock into shares of common stock. The...

BiomX Presents Positive Phase 1b/2a Clinical Trial Data for BX004 at Key ConferencesGAITHERSBURG, Md. and NESS ZIONA, Israel, May 30, 2024 - BiomX Inc. (NYSE American: PHGE), a clinical-stage company specializing in the...

BiomX, a leading industry pioneer in the employment of phage therapies in medicine, has announced that they will be presenting data from their groundbreaking Phase 1b/2a study of BX004 at the 34th European Congress of C...

BiomX, a leading biotechnology company specializing in the development of precision phage therapies, has announced the successful completion of its acquisition of Adaptive Phage Therapeutics. This strategic merger has r...

In an exciting turn of events, BiomX has announced its entry into a merger agreement with Adaptive Phage Therapeutics, accompanied by a concurrent $50 million financing. This strategic collaboration is set to create a g...